Skip to main content
. 2021 Sep 18;16:1691–1702. doi: 10.2147/CIA.S326095

Table 3.

Oral Health Status in Dentate Patients, in Relation to Comorbidities and Medications (n=181)

Variable Number of Teeth Pocket Depth DFT
< 20 Teeth ≥ 4 mm > Mean 15
N= 80 (44%) N= 147 (81%) N= 94 (52%)
Comorbidities
Diabetes 0.58 (0.25–1.39) 0.68 (0.21–2.22) 0.37 (0.15–0.94)
 p-value 0.224 0.520 0.037
Heart disease 1.26 (0.64–2.44) 0.38 (0.15–0.95) 0.99 (0.51–1.94)
 p-value 0.505 0.039 0.997
Dementia 0.82 (0.32–2.07) 0.89 (0.27–2.93) 0.75 (0.29–1.96)
 p-value 0.673 0.849 0.556
COPD 0.33 (0.13–0.83) 1.03 (0.32–3.35) 0.36 (0.13–0.99)
 p-value 0.019 0.961 0.048
Medications
Polypharmacy ≥5a 0.62 (0.31–1.24) 0.56 (0.24–1.28) 0.40 (0.20–0.81)
 p-value 0.176 0.167 0.011
Diuretics 0.62 (0.32–1.20) 0.32 (0.12–0.86) 0.39 (0.20–0.78)
 p-value 0.158 0.023 0.007
Anticoagulants 1.13 (0.60–2.12) 0.47 (0.21–1.07) 0.77 (0.41–1.44)
 p-value 0.710 0.073 0.414
Inhalation drugsb 0.29 (0.12–0.67) 1.97 (0.80–4.85) 0.41 (0.18–0.93)
 p-value 0.004 0.138 0.032
ACE/ARB 1.65 (0.87–3.14) 0.63 (0.27–1.46) 0.61 (0.32–1.15)
 p-value 0.128 0.286 0.127
Sedatives 0.78 (0.39–1.54) 0.67 (0.27–1.65) 0.57 (0.28–1.14)
 p-value 0.468 0.382 0.113
Anticholinergicsc 0.49 (0.14–1.64) 0.71 (0.14–3.46) 0.62 (0.19–2.07)
 p-value 0.245 0.669 0.440
Use of ≥2 AC drugsd,* 0.32 (0.15–0.70) 1.76 (0.71–4.34) 0.31 (0.14–0.66)
 p-value 0.004 0.149 0.003

Notes: aPolypharmacy, defined as use of 5 or more drugs regularly. bInhalation drugs used for obstructive lung diseases. cDrugs with strong anticholinergic effect. dPatients using two or more drugs with strong anticholinergic effect. All variables were adjusted for age, gender, and comorbidity index (CCI), and the variable marked with *was also adjusted for polypharmacy. Values presented as OR (95% CI). P-values of <0.005 are presented in bold text.

Abbreviations: OR, odds ratio; CI, Confidence interval; COPD, chronic obstructive pulmonary disease; RA, rheumatoid arthritis; CCI, Charlson comorbidity index; eGFR, Estimated glomerular filtration rate; ACE/ARB, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; AC, strong anticholinergic drugs.